CMS Formalizes Medicare Drug Price Negotiations Starting With 2029 Cycle, Allows Selection of 20 Drugs Annually
Key Facts
On November 5, the Centers for Medicare & Medicaid Services (CMS) issued a final rule formalizing the Medicare drug price negotiation program beginning with the 2029 price applicability year, establishing a regulatory framework for future cycles. The rule allows the agency to select up to 20 drugs covered under Part B and/or Part D for negotiation in 2029 and each subsequent year. It also allows renegotiation of selected drug prices if they meet eligibility and selection criteria. CMS said the rule builds on policies in place for the first three negotiation cycles and introduces requirements for the fourth cycle and beyond. It said the focus includes continuing to increase transparency in the program.
To date, CMS has implemented the program for price applicability years 2026 through 2028 through program instructions and other forms of guidance, as permitted by law. The final rule moves the implementation framework into regulation for subsequent years, with its provisions beginning to apply to the 2029 cycle. The regulations take effect on December 5, 2026, according to the Federal Register. This separates the rule’s effective date from the price year to which the negotiation provisions will apply. The fourth cycle marks the transition to rules governing later cycles.
Among the new provisions is the treatment of certain fixed-combination drugs that represent new formulations of existing drugs. CMS said the policy aims to avoid creating an incentive for a manufacturer to move patients to the drug’s new formulation to circumvent application of the maximum fair price. The rule also includes a temporary minimum for certain eligible drugs made by small biotechnology companies in the 2029 and 2030 price applicability years. According to the agency, this minimum prevents CMS from making a counteroffer or accepting an offer below a specified threshold for certain of those drugs. The agency links the two measures to how negotiation rules apply to specific drug categories and circumstances.
The rule includes coverage requirements affecting Part D beneficiaries. In 2026 and each subsequent year, plans must include every selected drug covered under Part D on their formularies when the maximum fair price is effective, according to CMS. The rule also sets a cap on what plans pay pharmacies and other dispensing entities, equal to the maximum fair price plus a dispensing fee. CMS Administrator Mehmet Oz said the rule gives the agency “additional tools to negotiate better deals and deliver greater savings for taxpayers and beneficiaries.” He added that it aims to improve health outcomes for older adults who rely on Medicare for prescription drugs.
The agency’s earlier estimates indicate the savings associated with the first cycle, not an estimate of the new rule’s impact. CMS said negotiated prices for the ten drugs would have generated about $6 billion in savings, or nearly 22%, had they been in effect in 2023, compared with Medicare net prices after rebates and certain fees and payments. It also estimated that about 9 million beneficiaries use at least one of the ten selected drugs. It projected total out-of-pocket savings for those beneficiaries of $1.5 billion in 2026. These figures relate to the first cycle and the agency’s estimates for it.
The next steps for the fourth cycle begin with publication of the selected drug list by February 1, 2027. The list will include up to 20 Part B and/or Part D drugs selected for the 2029 price year, and any drugs CMS decides to renegotiate; the agency will also publish a list of up to 30 eligible drugs with the highest spending from which the drugs were selected. Participating manufacturers must sign program agreements by February 28, 2027. March 1, 2027, is the deadline for manufacturers and the public to submit data. Agreed prices for drugs selected or renegotiated in the 2029 cycle will take effect on January 1, 2029.